Lymphangi leiomyomatosis and *TSC2*^{-/-} Cells

Thomas N. Darling, M.D., Ph.D.,¹ Gustavo Pacheco-Rodriguez, Ph.D.,² Alfredo Gorio, Ph.D.,^{3,4}
Elena Lesma, Ph.D.,³ Cheryl Walker, Ph.D.,⁵ and Joel Moss, M.D., Ph.D.²

Abstract

The cells comprising pulmonary lymphangi leiomyomatosis (LAM) and renal angiomyolipomas (AMLs) are heterogeneous, with variable mixtures of cells exhibiting differentiation towards smooth muscle, fat, and vessels. Cells grown from LAM and AMLs have likewise tended to be heterogeneous. The discovery that LAM and AMLs contain cells with mutations in the *TSC1* or *TSC2* genes is allowing investigators to discriminate between “two-hit” cells and neighboring cells, providing insights into disease pathogenesis. In rare cases, it has been possible to derive cells from human tumors, including AMLs and TSC skin tumors that are highly enriched for *TSC2*^{-/-} cells. Cells derived from an Eker rat uterine leiomyoma (ELT3 cells) are *Tsc2*-null and these have been used in a rodent cell models for LAM. Further improvements in the ability to reliably grow well-characterized *TSC2*^{-/-} cells from human tumors are critical to developing *in vitro* and *in vivo* model systems for studies of LAM pathogenesis and treatment.

Introduction

PATIENTS WITH LYMPHANGIOLEIOMYOMATOSIS (LAM) develop cystic changes in their lungs, cystic fluid-filled masses involving their axial lymphatics, and renal tumors called angiomyolipomas (AMLs). These diverse abnormalities in multiple organs share a proliferation of smooth muscle-like cells called LAM cells.¹ The observation that LAM, in addition to occurring sporadically in adult women, frequently develops in women with tuberous sclerosis complex (TSC), provided a clue to the pathogenetic mechanism generating LAM cells. TSC is caused by mutations in either the *TSC1* or *TSC2* genes, which lead to a dysfunctional TSC1–TSC2 complex (also referred to as hamartin–tuberin) and mammalian target of rapamycin complex 1 (mTORC1) activation. These same biochemical abnormalities are observed in LAM cells from patients with sporadic LAM.² Herein we review the genetic, molecular, and cellular abnormalities in LAM cells and related human and rat cells that are null for *TSC2*, and point out the potential significance of these findings for our understanding of LAM pathogenesis and treatment.

Cellular Composition of Lymphangi leiomyomatosis

Lung LAM cells develop within nodular structures as spindle-shaped (proliferative) and epithelioid cells. The

spindle-shaped cells express α -smooth muscle actin (SMA), vimentin, desmin, proliferating nuclear antigen (PCNA), and Ki-67. On the other hand, epithelioid LAM cells in addition to expressing smooth muscle antigens, also express melanoma markers such as gp100 (a splice variant of Pmel17), MART-1, CD63, and PNL2.³ Spindle-shaped and epithelioid cells are immunophenotypically distinct and yet it is possible that they are derived from a common progenitor. A related tumor type, called perivascular epithelioid cell neoplasms (PEComas), is composed of mesenchymal cells, possessing a myomelanocytic phenotype.^{4,5}

LAM nodular structures are coated by hyperplastic type II pneumocytes, which appear proliferative and ultrastructurally have apical microvilli, electron-dense lamellar bodies, and cytoplasmic projections.⁶ The hyperplastic nature of the type II pneumocytes may be related to the expression of thyroid transcription factor-1 which regulates, in part, synthesis of surfactant proteins.^{7,8} The role of these cells in the pathogenesis of LAM is poorly understood.

Lymphatic endothelial cells and mast cells are also major cellular constituents of LAM lung nodules. Lymphatic endothelial cells (LEC) were identified by their reactivity with anti-VEGFR-3 and anti-podoplanin antibodies.⁹ Numerous lymphatic channels lined by lymphatic endothelial cells are found within LAM lung nodules. LEC may surround LAM

¹Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland.

²Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

³Laboratory of Pharmacology, Department of Medicine, Surgery and Dentistry, Faculty of Medicine, Università degli Studi di Milano, Milan, Italy.

⁴Clinical Pharmacology, IRCCS Humanitas, Milan, Italy.

⁵Department of Carcinogenesis, The University of Texas M.D. Anderson Cancer Center, Smithville, Texas.

cells in LAM cell clusters, which are seen in LAM chylous effusions.⁹ Mast cells within the LAM nodule were identified by reactivity with anti-CD117 antibodies, which recognizes c-Kit, a 145-kD transmembrane protein that is highly expressed by mast cells.¹⁰

LAM Cells

With multiple cell types comprising LAM nodules, it appears that the interplay of these cells, as well as cells in neighboring tissues, is involved in the pathogenesis of LAM. However, only LAM cells appear to have TSC gene mutations. The mutations found most frequently in sporadic LAM inactivate the *TSC2* tumor suppressor gene.^{11–13}

Lung LAM cells have been grown from explants of lung tissue obtained at the time of transplant and from diagnostic biopsies. LAM cells have been grown in different culture systems directly from explants or following enzymatic digestion. A major challenge is the finding that all approaches yield a heterogeneous population of cells. All cells grown from explants of LAM lung do not show loss of heterozygosity (LOH) at the *TSC2* locus, suggesting that these cultures contain LAM cells mixed with other cells lacking the genetic features of LAM cells. Consistent with this interpretation, subpopulations of cells are immunoreactive with antibodies to SMA and gp100, and some nuclei show allelic deletion of the *TSC2* gene (Fig. 1). Methods are being developed to isolate and propagate pure populations of LAM cells. When populations are isolated from heterogeneous cultures using fluorescence-activated cell sorting, LOH or allelic imbalance for *TSC2* is observed mostly in cells positive for the cell surface marker CD44v6 (Fig. 2). Unfortunately, the same antibody used to isolate these cells also induces cell death, blocking efforts to grow a pure population of cells.¹⁴

Loss of *TSC2* protein function results in hyperactivation of the mTORC1 signaling pathway leading to dysregulated cell growth, and biochemical events related to mTORC1 activation have been used to characterize cells derived from LAM nodules. Cells derived from LAM nodules exhibit hyperphosphorylation of p70S6K and ribosomal protein S6,¹⁵ markers commonly used to assess mTORC1 activation. Hyperphosphorylation of S6 cannot be relied upon exclusively as a marker for LAM cells, however, because its presence does not always equate with loss of *TSC2* function. For example, malignant cells from melanoma often possess hyperactivated S6 but without *TSC2* mutations.¹⁶ Furthermore, S6 phosphorylation may result from activation of phospholipase D and protein kinase C,¹⁷ and low expression of DEPTOR could result in activation of mTOR.¹⁸ The potential for hyperphosphorylation of S6, independent of mutations in *TSC2*, supports the scientific concern that LAM cells should be genetically characterized. In addition, it may be necessary to characterize the cells epigenetically, since methylation of the *TSC2* promoter has been shown to play a role in AMLs.¹⁹

Multiple mitogens and growth signaling pathways may drive LAM cell proliferation. Among these mitogens are angiotensinogen II,¹⁰ insulin-like growth factor,²⁰ INF- γ and INF- β ,^{21,22} plasminogen,²³ prostaglandins,²⁴ and PDGF.²⁵ Interestingly, angiotensin II could also upregulate VEGF production. Altogether, these data suggest that the microenvironment of the LAM cell may generate factors responsible for their proliferation.

FIG. 1. Phenotypic and genotypic heterogeneity in LAM cell cultures. Reaction of cells cultured from LAM lung (A) or pulmonary artery smooth muscle cells (PASM) (B) with monoclonal antibody against SMA. Reaction of cultured LAM cells (C) and MALME-3M melanoma cells (D) with monoclonal antibody HMB-45. Fluorescence *in situ* hybridization (FISH) for *TSC1* (green) and *TSC2* (red) on cells grown from LAM lungs (E–G), reveals two populations of cells (E) with some nuclei showing the expected presence of two signals for each allele, *TSC1* (arrows) and *TSC2* (arrowheads) (F) and other nuclei exhibiting a single signal for *TSC2* (G). Bar, 20 μ m. (Reference 14, reproduced with permission. Copyright 2007 American Association for Cancer Research).

Sporadic LAM affects adult women almost exclusively, suggesting that tumor growth is hormonally regulated. Lung LAM cells express estrogen and progesterone receptors^{26–28} and patients treated with tamoxifen and progesterone showed downregulation of these respective receptors.²⁹ In mice xenografted with *Tsc2*-null cells derived from Eker rats, 17- β -estradiol increased metastasis in both male and female mice.³⁰ Estrogen also enhanced the growth of liver hemangiomas in *Tsc* mice.³¹ Consistent with hormonal effects on LAM cells, it has been suggested that estrogens induce metalloprotease production by on LAM cells, which affects their invasive properties.³² Although all of these findings appear congruent with the pathogenesis of lung LAM, a clear effect of estrogens on lung LAM cells cannot be concluded because of the lack of genetic information on cells that have been studied and the use of non-human cell lines.

FIG. 2. Enrichment of LAM cells showing loss of heterozygosity (LOH) at the *TSC2* locus. Cells were incubated with CD44-R-phycoerythrin and CD44v6-fluorescein antibodies for fluorescence-activated cell sorting. (A) Side (SSC) and forward (FSC) scatter; cells within the R1 gate were selected for sorting. (B) Four populations (CD44⁻CD44v6⁻, CD44⁺CD44v6⁻, CD44⁻CD44v6⁺, and CD44⁺CD44v6⁺) of cells defined by reaction with CD44-RPE and/or CD44v6-FITC antibodies. (C) LOH analysis of sorted cells. Chromatograms show profiles for the microsatellite marker Kg8. Controls are samples from cells before sorting. Arrows show the position of the missing allele. (Reference 14, reproduced with permission. Copyright 2007 American Association for Cancer Research).

LAM cells are histologically benign, so it was surprising when evidence began to accumulate that LAM cells were able to metastasize. Although the initial site of LAM and the cell of origin have not been identified, transplanted lungs showed recurrence of LAM due to invasion by LAM cells derived from the recipient.^{33–37} This behavior is in agreement with the finding of disseminated LAM cells in the blood and lymphatic circulation.³⁸ Thus, an important challenge is to define molecular aspects of LAM cell metastasis.

CD44v6 is expressed by many cancer cells and appears to be important for metastasis. It is expressed by LAM lung lesions, as well as in cultured cells grown from LAM lungs (Fig. 2).¹⁴ CD44v6 splice variant interacts with integrins and multiple receptors (e.g., hepatocyte growth factor receptor). The multiple interactions of CD44 and its splice variants suggest that it may participate in cell-to-cell interactions within the LAM nodule microenvironment and with the extracellular matrix.

It has been suggested that LAM cell invasiveness and migration are due to the activation of the GTPases Rac1 and Rho,

which are, in part, regulated by TSC2^{25,39} and that estrogens drive the synthesis of metalloproteases by LAM cells.³² These studies were carried out with cells obtained from LAM lungs treated with collagenase D and elastase.¹⁵ The cells obtained express TSC2 and contain high levels of phosphorylated S6. As suggested by these authors, the use of these type of cell cultures present limitations due to the heterogeneity.²⁵ Therefore, it is difficult to conclude that the LAM cells lacking TSC2 function are responsible for invasion and migration and that they respond to specific stimuli. To study cell signaling pathways in LAM cells, it would be advantageous to use a homogeneous population of human LAM cells with mutations in TSC2.

Global gene expression analysis of microdissected LAM lung cells of patients with sporadic LAM identified a set of transcripts that distinguished lung LAM cells from smooth muscle and melanoma cells (GEO database GSE12027). Some chemokines were differentially expressed and may participate in attraction and anchoring of cells to sites of metastasis. In agreement, CCL2/MCP-1 was increased in bronchoalveolar

lavage fluid of LAM patients compared to healthy volunteers. Furthermore, LAM cells within the lung lesions expressed a distinct group of chemokine receptors, including CCR2, CXCR4, CCR7, and CCR10. It was also observed that CCL2/MCP-1 selectively mobilized cells from explants of lungs of LAM patients with *TSC2* LOH and that CCL2 could participate in a positive feedback loop of metastasis.⁴⁰

In summary, obtaining LAM cells that are clonal or highly enriched has been challenging due to the multiple cell types derived from lungs and the heterogeneity of LAM nodules. To understand the role of signaling pathways in LAM pathogenesis and response to treatment, LAM cells that are well characterized genetically, phenotypically, and functionally would be of use to the LAM scientific community.

Cellular Composition of Angiomyolipomas (AMLs)

AMLs were first described as large renal tumors comprised of fat, muscle, and blood vessels.⁴¹ Renal AMLs may occur in otherwise healthy individuals or in association with TSC or sporadic LAM. Up to 80% of TSC patients eventually develop AMLs, and women develop them more frequently than men. As in LAM, this may suggest hormonal regulation of growth, and AMLs often express receptors for both estrogen and progesterone.^{42,43} Smooth muscle cells of pulmonary LAM and AMLs appear to be closely related histologically, immunohistochemically, and in some cases genetically, suggesting a model in which renal AML cells migrate or metastasize to the lung, resulting in pulmonary LAM.³⁸ Metastases of angiomyolipoma cells to the lung may cause development of LAM.^{44,45} AMLs sustain second-hit mutations in either *TSC1* or *TSC2*, as indicated by LOH analysis.^{46,47}

The histologically distinct cell types comprising AMLs appear to be derived from perivascular epithelioid cells capable of differentiating into cells with features of melanocytes, smooth muscle, and fat.^{48,49} In addition, AMLs contain multiple vessels types, four of which (cellular, hemangiopericytic, glomeruloid, and aneurysmatic) have loss of heterozygosity (LOH), indicating that they are neoplastic while one (collagenous) does not have LOH.⁵⁰ LOH of vessels, smooth muscle, and fat cells is consistent with the hypothesis that AMLs are derived from a mesenchymal precursor that retains the ability to differentiate into multiple different lineages.

Cells from AMLs

In 2001, Arbiser *et al.* described the generation of cultures of human AML cells, carrying phenotypic characteristics of cells derived from AMLs.⁵¹ The stable cell line was obtained by sequentially introducing SV40 large T antigen and human telomerase into tumor cells from a sporadic human AML of a patient not affected by TSC. In another study, the cells of a primary culture were isolated from a LAM-associated renal angiomyolipoma. These cells carried inactivating mutations in both alleles of the *TSC2* gene (*TSC2* exon 16 missense mutation G1832A) and expressed estrogen receptor α , estrogen receptor β , and androgen receptor.⁵² Exposure of these cells to estradiol and tamoxifen citrate promoted their growth.⁵² Tamoxifen acts as an estrogen agonist in these cells, in contrast to tamoxifen's estrogen antagonist action in Eker rat-derived ELT-3 cells.⁵³ The stimulated growth was associated with phosphorylation of p42/44 mitogen-activated protein kinase (MAPK) and increased expression of c-myc, indicating an

activation of nongenomic and genomic signaling pathways, respectively, in cultured angiomyolipoma cells.⁵² Consistent with the observation that cells lacking tuberlin have constitutive hyperphosphorylation of p70S6K and its ribosomal substrate S6, these cells showed increased S6 phosphorylation.^{15,17,54} In LAM-associated and sporadic AMLs, the mTOR p70S6K signaling pathway is highly activated in relation to *TSC1/TSC2* mutation.⁵⁵ The limitation of this cell model was the number of studies since the entire primary culture was lost after a few passages.

Two cell populations were described in 2005 that were derived from an AML of a *TSC2* female patient.⁵⁶ These cell populations were isolated, characterized, and separated by sequential subcloning in order to obtain homogeneous cultures. One cell population had a flat and elongated appearance and these cells were alpha actin-positive smooth muscle-like cells (ASM), while the other had an epithelial-like morphology and were keratin 8/18-positive. Both populations were reactive to HMB-45, a monoclonal antibody that recognizes LAM lung cells.^{14,31} The epithelial-like cells were markedly reactive with anti-RhoA antibodies. Both cell populations contained a germline *TSC2* exon 18 mutation, consisting of a base-pair change in the codon for amino acid 698, leading to replacement of lysine with a stop codon (K698X). Only smooth muscle-like cells exhibited LOH and did not express tuberlin (*TSC2*^{-/-} ASM cells), whereas in the epithelial-like cells the mutation was heterozygous and the cells expressed tuberlin. LOH in *TSC1* or *TSC2* has been documented in AMLs, cardiac rhabdomyomas, and LAM cells, and only rarely in cerebral cortical tubers and skin lesions.^{11,47,57,58}

More recently, another alpha actin-positive cell population was isolated and characterized, this time from an AML of a male patient with a germline mutation in *TSC2*.¹⁹ These cells were reactive with HMB45 and anti-CD44v6 antibodies, while tuberlin was undetectable. These cells bear a germline mutation in *TSC2* at the junction between intron 8 and exon 9, but they lack LOH. The loss of tuberlin expression is the consequence of methylation of the *TSC2* promoter (*TSC2*^{-/meth} ASM cells), suggesting that angiomyolipoma pathogenesis might also originate from epigenetic defects. The involvement of methylation in the inhibition of the *TSC2* gene has been confirmed by expression of tuberlin following treatment with chromatin-remodeling agents such as trichostatin A and 5-azacytidine.¹⁹ Moreover, these agents downregulate the constitutive S6 phosphorylation. Methylation of promoter regions is a common feature in human cancer.

In spite of the different genetic mutation, *TSC2*^{-/-} and *TSC2*^{-/meth} ASM cells share proliferative and biochemical characteristics. Their growth and proliferation required epidermal growth factor (EGF) that cannot be replaced by insulin like-growth factor 1 (IGF-1) (Fig. 3A).^{19,56} *TSC2*-deficient cells secrete IGF-1, which may act as a survival factor by promoting the expression of survivin.⁵⁹ The EGF-dependent growth is related to the lack of tuberlin since transfection of the *TSC2* gene in *TSC2*^{-/-} ASM cells and the treatment of *TSC2*^{-/meth} ASM cells with 5-azacytidine reduced their proliferation to a normal rate, decreased S6 phosphorylation and eliminated the requirement of EGF for growth (Figs. 3B, 3C, and 3D).^{19,60} Blockade of either EGF or IGF-1 receptors with specific antibodies resulted in cell death (Fig. 3A).^{19,56} The EGF receptor signaling pathway regulates cell differentiation, proliferation, migration, angiogenesis, and apoptosis, all of which become

FIG. 3. (A) Comparison of the proliferation of *TSC2*^{-/-} (solid line) and *TSC2*^{meth} (dashed line) ASM cells in presence or absence of EGF, and with anti-EGFR or anti-IGF-1R antibodies. Cell number at the beginning of the treatment was considered 100%. The growth rates of the two cell lines were similar. (B) Constitutive phosphorylation of S6 (Ser235/236) was markedly decreased by *TSC2* transfection in *TSC2*^{-/-} ASM cells and by trichostatin A (TSA) in *TSC2*^{meth} ASM cells. (C) Tuberin was undetectable by immunocytochemistry in *TSC2*^{-/-} ASM cells, but it was expressed in these cells following *TSC2* transfection. (Reference 60, Copyright 2008 Lesma et al.). (D) Following incubation with TSA (3.3 μ M) for 72 h or 5-azacytidine (5-AZA) (1 μ M) for 96 h, tuberin expression was increased in *TSC2*^{meth} ASM cells. (Reference 19, reproduced with permission. Copyright 2009 American Society for Investigative Pathology).

deregulated in cancer cells. Anti-EGF receptor antibody has been shown to be efficacious in several types of cancer, such as colorectal and head and neck cancers⁶¹ and it may also be of therapeutic value in TSC.

Rapamycin has been recently reported to be effective in promoting the regression of TSC AMLs.⁶² The exposure of *TSC2*^{-/-} ASM cells to rapamycin resulted in a cytostatic action only when the drug was added at the time of plating the cells, otherwise the drug was rather ineffective. *TSC2*^{meth} ASM cells are more responsive to rapamycin and the cytostatic effect is observed at any time. These data are consistent with the effect of rapamycin in a large trial that reported the tendency of AMLs to increase in volume after therapy was stopped.⁶² In accordance with these results, rapamycin was highly effective in suppressing the growth of Tsc mouse kidney cystadenomas but a marked tumor regrowth occurred after stopping the drug.⁶³ The exposure to rapamycin and anti-EGF receptor antibody downregulated the constitutive S6 phosphorylation observed in *TSC2*^{-/-} and *TSC2*^{meth} ASM cells.^{15,54} Growth factors, such as EGF, lead to Erk-1 and Erk-2 phosphorylation through the activation of MAPK that regulates tuberin. Both rapamycin and anti-EGF receptor

antibody inhibited Erk phosphorylation with anti-EGF receptor antibody being more effective. All together these data support the regulatory role of MAPK pathway in *TSC2* ASM cell proliferation.

Cellular Composition of TSC skin tumors

Patients with TSC develop multiple benign skin tumors that are located on the face (angiofibromas and forehead plaques), back (shagreen patch), and nails (ungual fibromas). TSC skin tumors may be present at birth, but they typically develop throughout childhood, appearing as small red papules or larger irregular plaques.⁶⁴ They are composed mostly of fibrous tissue, and fibroblast-like cells are a major cell population. These fibroblast-like cells (variously called fibroblasts, fibroblastic cells, interstitial fibroblasts, and stroma cells) have been the focus of most studies of TSC skin tumors.

In early histological studies of angiofibromas and ungual fibromas, investigators observed that fibroblast-like cells are larger than normal fibroblasts, stellate or polygonal in shape, and sometimes multinuclear.⁶⁵⁻⁶⁷ Fibroblast-like cells are interspersed among increased amounts of collagen and dilated

vessels, including blood and lymphatic endothelial cells.^{68,69} The epithelium overlying the tumors is often thickened due to a proliferation of keratinocytes.⁷⁰ Once the genetic basis for TSC was uncovered and antibodies were generated against human TSC1 and TSC2 proteins, it was possible to test for aberrant expression of these proteins in TSC tumors. Immunohistochemistry revealed that a significant proportion of TSC skin tumors showed loss of TSC1 and/or TSC2 expression in the interstitial fibroblast-like cells.^{71,72} Other cellular constituents, such as vessels and keratinocytes, did not show loss of TSC1 or TSC2 expression.

Loss of TSC1 or TSC2 expression in the fibroblast-like cells suggested that these cells had sustained second-hit mutations in either *TSC1* or *TSC2*. Attempts to demonstrate a second-hit mutation in TSC skin tumors were mostly negative, and loss of heterozygosity (LOH) at the *TSC1* or *TSC2* locus was observed in only a few TSC skin tumors.^{47,58,73–75} Inability to detect LOH in most samples was likely due to the cellular heterogeneity of these tumors. This problem was surmounted by using fluorescence *in situ* hybridization to analyze individual nuclei, which documented allelic deletion for *TSC2* in dermal touch preparations of 8/8 angiofibromas and 6/7 periungual fibromas.⁷⁰ These results indicate that fibroblast-like cells are the two-hit cells in TSC skin tumors.

Loss of TSC1-TSC2 function in fibroblast-like cells is expected to lead to activation of mTORC1 and hyperphosphorylation of ribosomal protein S6. When sections of TSC skin tumors were stained for phospho-S6, immunoreactivity was observed in the fibroblast-like cells in the dermis as expected (Fig. 4A), whereas fibroblasts in normal-appearing skin were negative (Fig. 4B).⁷⁰ Surprisingly, the epidermis overlying tumors also stained positive for phospho-S6. Keratinocytes did not show genetic alterations at the *TSC2* locus, and positive staining in the epidermis may be caused by the release of paracrine factors from fibroblast-like tumor cells.⁷⁰ The potential for paracrine activation of phospho-S6 represents a potential pitfall in using phospho-S6 as the sole marker for tumor cells.

Cells from TSC Skin Tumors

Fibroblast-like cells can be grown from tissue explants of TSC skin tumors. Nearly all cultures of angiofibromas and ungual fibromas contain two-hit cells, but they generally comprise a minority of the cells⁷⁰ and cultures do not show LOH.⁷⁶ This heterogeneity is similar to that typically observed when cells are grown from explanted LAM lung nodules.¹⁴ Heterogeneity in skin tumor cultures was further dissected by combining immunocytochemistry for phospho-S6 with fluorescence *in situ* hybridization for deletion of *TSC2*. Individual cells were observed that were phospho-S6 negative with 2 signals for *TSC2*, and phospho-S6 positive with 1 signal for *TSC2* (Fig. 4C). These results are consistent with mixture of one-hit with two-hit cells, with mTORC1 activation in the two-hit cells. In rare instances, cells were grown that exhibited biallelic mutations in *TSC2*, undetectable TSC2 protein, and constitutive activation of mTORC1.⁷⁷ These *TSC2*^{-/-} cells will be useful for future studies on the effects of loss of TSC2 in TSC skin tumors, but most studies to date have used tumor-derived cells that are either genetically uncharacterized or heterogeneous with one-hit and two-hit cells.

Cells grown from angiofibromas and ungual fibromas express fibroblast markers such as HSP47 and vimentin, but

FIG. 4. Heterogeneity of mTORC1 activation in TSC skin tumors and cells grown from TSC skin tumors. Sections of normal-appearing skin (A) or periungual fibromas (B) were stained for phosphorylated ribosomal protein S6 (red). Fibroblast-like cells in the dermis of tumors, but not fibroblasts in a paired sample of normal-appearing skin, are immunoreactive for phospho-S6. The epidermis of the TSC skin tumor also shows immunoreactivity for phospho-S6, due to release of paracrine factors by tumor fibroblast-like cells. (C) Staining for phospho-S6 in cells with allelic deletion of *TSC2*. Cells grown from a periungual fibroma were analyzed by combined immunocytochemistry for phospho-S6 (green) and fluorescence *in situ* hybridization for *TSC2* (red signals, indicated by arrowheads), using DAPI to stain nuclei (blue). The nucleus on top with two signals for *TSC2* shows undetectable phospho-S6, and the nucleus below with allelic deletion of *TSC2* shows strong staining for phospho-S6.

are immunonegative for SMA, S-100, CD14, and CD68.^{78,79} Whereas their immunophenotype is similar to fibroblasts, they exhibit several differences with normal fibroblasts. In one study, angiofibroma cells displayed reduced proliferation and increased senescence compared to normal fibroblasts,⁸⁰ while another study found comparable levels of BrdU incorporation, a prolonged S phase, and increased apoptosis.⁷⁶ These results are difficult to reconcile with studies showing that loss of function of the TSC1–TSC2 complex results in increased proliferation,⁸¹ but it may be related to a phenomenon observed in hematopoietic stem cells whereby deletion of *TSC1* produces transient expansion of stem cells, followed by loss of long-term repopulating potential.⁸²

Fibroblast-like cells grown from TSC skin tumors have been used to investigate potential mechanisms of tumorigenesis. TSC skin tumors are highly angiogenic,⁶⁸ and loss of TSC2 function results in increased expression of the angiogenic cytokine VEGF.^{83,84} Gene expression arrays were used to identify additional growth factors or chemokines that might play roles in TSC skin tumorigenesis. Two genes that are highly overexpressed by fibroblast-like cells are monocyte chemoattractant protein-1 (MCP-1, or CCL2)⁷⁹ and epiregulin.⁷⁰ MCP-1 is a chemokine that attracts peripheral blood monocytes. It is also highly expressed in skin of transgenic mice, having a dominant negative allele of *Tsc2*.⁸⁵ Overexpression of MCP-1 in TSC skin tumors is associated with recruitment of mononuclear phagocytes into the tumors, where they may further stimulate angiogenesis.⁷⁹ Epiregulin is an epidermal growth factor (EGF)-family member that may induce changes in the epithelium overlying TSC skin tumors.⁷⁰

Tsc2^{-/-} Cells from Animal Tumors

Several rodent models of Tsc deficiency have been developed, and murine cell lines established from these animals are widely available. Like *bone fide* LAM cells, for which these lines are often used as a surrogate, these cells lack either Tsc1 or Tsc2. As a result, they recapitulate the signaling defect caused by loss of Tsc in LAM cells. Specifically, these lines exhibit upregulation of mTORC1 signaling and downregulation of AKT activity. This shared signaling defect has made these cells useful in preclinical studies, where they have proven their utility for evaluating efficacy of targeted therapies for LAM, such as mTORC1 inhibition using rapamycin and its analogs.

Cells Derived from Knockout Mice

Germline inactivation of both alleles of the *Tsc1* or *Tsc2* tumor suppressor gene in mice is embryonic lethal.^{86–89} However, mouse embryo fibroblasts (MEFs) have been isolated from both Tsc1 and Tsc2 knockout mice. Interestingly, establishment of Tsc-null MEF lines in culture requires inactivation of p53, which was achieved by crossing Tsc heterozygous mice with p53 heterozygotes.^{87,90} The requirement that p53 be lost to establish Tsc-deficient MEFs in culture suggests that loss of Tsc function results, directly or indirectly, in dysregulation of this tumor suppressor, and that abrogation of p53 function(s) is required to overcome senescence and/or induce immortalization in this setting of Tsc deficiency. Like tumors that arise in Tsc-deficient animals, and LAM lesions, Tsc-null MEFs exhibit upregulation of mTORC1 signaling. Recently, MEF cell lines have also been isolated from

mice expressing a hypomorphic Tsc2 allele (*Tsc2^{del3/del3}*), and these also display activated mTORC1 signaling.⁹¹

In addition to MEF cell lines, a line of neuroepithelial progenitor (NEP) has also been established from Tsc2-null mice.⁹² These cells exhibit an aberrant differentiation pattern resembling giant cells of human tumors and express β -III tubulin and GFAP. Like Tsc2-null MEFs, Tsc2-null NEP also exhibit upregulation of mTORC1 signaling.

Interestingly, in addition to downregulation of AKT, cell lines lacking Tsc also exhibit decreased IRS1 and PDGFR activity, thought to be due to feedback loops associated with constitutive upregulation of mTORC1^{90,93,94} and/or the requirement for Tsc2 as a co-factor for the kinase activity of mTORC2, which is responsible for AKT phosphorylation at S473.⁹⁵

Cells Derived from Tsc-Null Tumors

The most widely used cell lines are derived from tumors that arose in the Eker rat model for tuberous sclerosis. Eker rats are heterozygous for Tsc2,^{96,97} and are susceptible to spontaneous and carcinogen-induced tumors in the kidney (renal cell carcinoma:RCC),^{98,99} uterus (uterine leiomyoma),¹⁰⁰ as well as spleen and highly vascular areas of the skin (hemangiosarcoma).^{101,102} These rats also develop pituitary and brain lesions.^{103,104} Several cell lines have been isolated from spontaneous tumors of Eker rats. Lines have been derived from RCCs from these animals, termed ERC lines,⁹⁹ and from neoplastic/polycystic kidneys that develop in these animals when loss of the wild-type *Tsc2* allele occurs during development, the EKT lines.¹⁰⁵ In addition to these tumor-derived cell lines, lines have also been isolated from Eker rat embryos that are Tsc2-null (EEF-8) or Tsc2-proficient (EEF-4).¹⁰⁶

However, the cell lines most often utilized as surrogates for LAM are the proliferative smooth muscle cell lines isolated from Eker rat uterine leiomyomas, the ELT cell lines.¹⁰⁷ Like the proliferative smooth muscle cells of LAM lesions, these lines are Tsc2-null and have constitutively active mTORC1 signaling.¹⁰⁸ More importantly, these lines express estrogen and progesterone receptors, and retain their hormone responsiveness.^{109,110} Isogenic ELT3 cell lines, T3 and V3, re-expressing Tsc2 or vector control, respectively, have also been generated.¹¹¹ Recently, it has been demonstrated that in response to estrogen, ELT cells grown as subcutaneous tumors in SCID mice will migrate to the lung.³⁰ This important finding could potentially lead to the development of an exciting new *in vitro/in vivo* animal model for LAM.

Preclinical Studies Using Tsc-Deficient Cell Lines

As mentioned above, both Tsc1- and Tsc2-deficient cell lines exhibit upregulation of mTORC1 signaling. Not surprisingly, growth of these cell lines *in vitro* and as tumors in nude mice is inhibited by rapamycin and its analogs. The elevated S6K and S6 phosphorylation characteristic of dysregulated mTORC1 signaling in Tsc/p53-null MEFs is inhibited by rapamycin,⁸⁷ as is their growth in culture.⁹⁰ ELT smooth muscle cells are also inhibited by rapalogs *in vitro*.¹⁰⁸ Growth inhibition by rapamycin reflects what is seen *in vivo*, where growth of Tsc-deficient tumor cells is inhibited by rapamycin and its analogs in several mouse models, including nude mice bearing subcutaneous tumors derived from injection of Tsc/p53-null MEFs.¹¹² Similarly, tumor development

in Eker rats is inhibited by rapamycin, as is the growth of ELT3 cells in SCID mice.^{30,54,108}

Conclusions

The cellular microenvironments of LAM, AMLs, and TSC skin tumors are complex, with multiple cell-cell and cell-matrix interactions. It comes as no surprise that cells grown from these tumors also tend to be heterogeneous. The recent availability of methods to distinguish different cell populations based on genetic or molecular markers is providing new insights into disease pathogenesis and response to treatment. Further improvements in methodologies are needed to be able to reliably isolate and grow pure populations of LAM cells, as well as other cell populations comprising these tumors, in order to more accurately assess their relative contributions to tumor formation. This will allow the development and testing of new therapies that specifically target LAM cells or the interactions of LAM cells with neighboring cells or matrix.

Acknowledgments

This work was supported by the Intramural Research Program of the National Institutes of Health, National Heart, Lung, and Blood Institute, and TS080064 from the Congressionally Directed Medical Research Program (TND). The work of A. Gorio and E. Lesma was supported by the Ministero Superiore della Sanita (IRCCS Grant 2007–09 on rare diseases program), the Italian TSC Association, and the Italian Lymphangioleiomyomatosis Association. We thank the Tuberous Sclerosis Alliance and The LAM Foundation for patient referral. We thank Dr. Martha Vaughan for useful discussions and critical review of the manuscript.

Author Disclosure Statement

Drs. Darling, Pacheco-Rodriguez, Gorio, Lesma, Walker, and Moss have no conflicts of interest or financial ties to disclose.

References

1. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. *Cancer Control* 2006;13:276–285.
2. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. Molecular pathogenesis of lymphangioleiomyomatosis: Lessons learned from orphans. *Am J Respir Cell Mol Biol* 2007;36:398–408.
3. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. *J Histochem Cytochem* 2004;52:1537–1542.
4. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: The past, the present and the future. *Virchows Arch* 2008;452:119–132.
5. Folpe AL, Kwiatkowski DJ. Perivascular epithelioid cell neoplasms: Pathology and pathogenesis. *Hum Pathol* 2010;41:1–5.
6. Matsui K, Riemenschneider WK, Hilbert SL, et al. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. *Arch Pathol Lab Med* 2000;124:1642–1648.
7. Bohinski RJ, Di Lauro R, Whitsett JA. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. *Mol Cell Biol* 1994;14:5671–5681.
8. Margana RK, Boggaram V. Functional analysis of surfactant protein B (SP-B) promoter. Sp1, Sp3, TTF-1, and HNF-3alpha transcription factors are necessary for lung cell-specific activation of SP-B gene transcription. *J Biol Chem* 1997;272:3083–3090.
9. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. *Am J Surg Pathol* 2005;29:1356–1366.
10. Valencia JC, Pacheco-Rodriguez G, Carmona AK, et al. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. *Am J Respir Cell Mol Biol* 2006;35:40–47.
11. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. *Proc Natl Acad Sci USA* 2000;97:6085–6090.
12. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. *Am J Hum Genet* 1998;62:810–815.
13. Astrinidis A, Khare L, Carsillo T, et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. *J Med Genet* 2000;37:55–57.
14. Pacheco-Rodriguez G, Steagall WK, Crooks DM, et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. *Cancer Res* 2007;67:10573–10581.
15. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). *J Biol Chem* 2002;277:30958–30967.
16. Karbowiczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. *J Invest Dermatol* 2008;128:980–987.
17. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. *Growth Factors* 2007;25:209–226.
18. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell* 2009;137:873–886.
19. Lesma E, Sirchia SM, Ancona S, et al. The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. *Am J Pathol* 2009;174:2150–2159.
20. Valencia JC, Matsui K, Bondy C, et al. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. *J Invest Med* 2001;49:421–433.
21. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. *Cancer Res* 2004;64:3436–3443.
22. Goncharova EA, Goncharov DA, Chisolm A, et al. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human

- lymphangioleiomyomatosis-derived cell proliferation. *Mol Pharmacol* 2008;73:778–788.
23. Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: Potential role of serum response factor. *Am J Respir Cell Mol Biol* 2005;32:28–34.
24. Black JL, Ge Q, Boustany S, et al. *In vitro* studies of lymphangioleiomyomatosis. *Eur Respir J* 2005;26:569–576.
25. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. *Am J Respir Cell Mol Biol* 2006;34:473–480.
26. Colley MH, Geppert E, Franklin WA. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. *Am J Surg Pathol* 1989;13:803–807.
27. Berger U, Khaghani A, Pomerance A, Yacoub MH, Coombes RC. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. *Am J Clin Pathol* 1990;93:609–614.
28. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioid endothelioma, and sclerosing hemangioma of the lung. *Am J Clin Pathol* 1991;96:529–35.
29. Matsui K, Takeda K, Yu ZX, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. *Am J Respir Crit Care Med* 2000;161:1002–1009.
30. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. *Proc Natl Acad Sci USA* 2009;106:2635–2640.
31. El-Hashemite N, Walker V, Kwiatkowski DJ. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: A tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. *Cancer Res* 2005;65:2474–2481.
32. Glassberg MK, Elliot SJ, Fritz J, et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. *J Clin Endocrinol Metab* 2008;93:1625–1633.
33. Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. *N Engl J Med* 1996;335:1275–1280.
34. Nine JS, Yousem SA, Paradis IL, Keenan R, Griffith BP. Lymphangioleiomyomatosis: Recurrence after lung transplantation. *J Heart Lung Transplant* 1994;13:714–719.
35. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeier C, Lohrs U. Lymphangioleiomyomatosis: Recurrence after single lung transplantation. *Hum Pathol* 1997;28:1420–1423.
36. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: New insights into pathogenesis. *Hum Pathol* 2003;34:95–98.
37. O'Brien JD, Lium JH, Parosa JF, Deyoung BR, Wick MR, Trulock EP. Lymphangioleiomyomatosis recurrence in the allograft after single-lung transplantation. *Am J Respir Crit Care Med* 1995;151:2033–2036.
38. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. *Proc Natl Acad Sci USA* 2004;101:17462–17467.
39. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. *J Cell Biol* 2004;167:1171–1182.
40. Pacheco-Rodriguez G, Kumaki F, Steagall WK, et al. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. *J Immunol* 2009;182:1270–1277.
41. Eble JN. Angiomyolipoma of kidney. *Semin Diagn Pathol* 1998;15:21–40.
42. Henske EP, Ao X, Short MP, et al. Frequent progesterone receptor immunoreactivity in tuberous sclerosis-associated renal angiomyolipomas. *Mod Pathol* 1998;11:665–668.
43. Logginidou H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. *Chest* 2000;117:25–30.
44. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangioleiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. *Am J Respir Crit Care Med* 2003;167:976–982.
45. Maruyama H, Seyama K, Sobajima J, et al. Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene. *Mod Pathol* 2001;14:609–614.
46. Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, Kwiatkowski DJ. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. *Genes Chromosomes Cancer* 1995;13:295–298.
47. Niida Y, Stemmer-Rachamimov AO, Logrip M, et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. *Am J Hum Genet* 2001;69:493–503.
48. Martignoni G, Pea M, Bonetti F, et al. Carcinomalike monotypic epithelioid angiomyolipoma in patients without evidence of tuberous sclerosis: A clinicopathologic and genetic study. *Am J Surg Pathol* 1998;22:663–672.
49. Neumann HP, Schwarzkopf G, Henske EP. Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. *Semin Pediatr Neurol* 1998;5:269–275.
50. Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangioleiomyomatosis contain both neoplastic and non-neoplastic vascular structures. *Am J Pathol* 2003;162:491–500.
51. Arbiser JL, Yeung R, Weiss SW, et al. The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: Use of telomerase to obtain stable populations of cells from benign neoplasms. *Am J Pathol* 2001;159:483–491.
52. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. *Am J Physiol Lung Cell Mol Physiol* 2004;286:L694–700.
53. Howe SR, Gottardis MM, Everitt JJ, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth *in vitro* and *in vivo*. *Endocrinology* 1995;136:4996–5003.
54. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. *Cancer Res* 2002;62:5645–5650.
55. Robb VA, Astrinidis A, Henske EP. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas. *Mod Pathol* 2006;19:839–846.
56. Lesma E, Grande V, Carelli S, et al. Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis

- complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor. *Am J Pathol* 2005;167:1093–1103.
57. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. *J Neuropathol Exp Neurol* 2004;63:1236–1242.
 58. Henske EP, Scheithauer BW, Short MP, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. *Am J Hum Genet* 1996;59:400–406.
 59. Carelli S, Lesma E, Paratore S, et al. Survivin expression in tuberous sclerosis complex cells. *Mol Med* 2007;13:166–177.
 60. Lesma E, Grande V, Ancona S, Carelli S, Di Giulio AM, Gorio A. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM. *PLoS ONE* 2008;3:e3558.
 61. Vokes EE, Chu E. Anti-EGFR therapies: Clinical experience in colorectal, lung, and head and neck cancers. *Oncology (Williston Park)* 2006;20:15–25.
 62. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N Engl J Med* 2008;358:140–151.
 63. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. *Mol Cancer* 2009;8:38.
 64. Jozwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielek J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. *Int J Dermatol* 1998;37:911–917.
 65. Nickel WR, Reed WB. Tuberous sclerosis. Special reference to the microscopic alterations in the cutaneous hamartomas. *Arch Dermatol* 1962;85:209–226.
 66. Reed RJ, Ackerman AB. Pathology of the adventitial dermis. Anatomic observations and biologic speculations. *Hum Pathol* 1973;4:207–217.
 67. Sanchez NP, Wick MR, Perry HO. Adenoma sebaceum of Pringle: A clinicopathologic review, with a discussion of related pathologic entities. *J Cutan Pathol* 1981;8:395–403.
 68. Arbiser JL, Brat D, Hunter S, et al. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. *J Am Acad Dermatol* 2002;46:376–380.
 69. Glasgow CG, Taveira-Dasilva AM, Darling TN, Moss J. Lymphatic involvement in lymphangioleiomyomatosis. *Ann NY Acad Sci* 2008;1131:206–214.
 70. Li S, Takeuchi F, Wang JA, et al. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. *Proc Natl Acad Sci USA* 2008;105:3539–3544.
 71. Nguyen-Vu PA, Fackler I, Rust A, et al. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. *J Cutan Pathol* 2001;28:470–475.
 72. Fackler I, DeClue JE, Rust H, et al. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas. *J Cutan Pathol* 2003;30:174–177.
 73. Sepp T, Yates JR, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. *J Med Genet* 1996;33:962–964.
 74. Green AJ, Sepp T, Yates JR. Clonality of tuberous sclerosis hamartomas shown by non-random X-chromosome inactivation. *Hum Genet* 1996;97:240–243.
 75. Au KS, Hebert AA, Roach ES, Northrup H. Complete inactivation of the TSC2 gene leads to formation of hamartomas. *Am J Hum Genet* 1999;65:1790–1795.
 76. Wataya-Kaneda M, Kaneda Y, Hino O, et al. Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis. *Arch Dermatol Res* 2001;293:460–469.
 77. Li S, Wang J-a, Pacheco-Rodriguez G, Moss J, Darling T. Rapamycin inhibits proliferation of cells from TSC skin tumors. *AACR Meeting Abstracts* 2007;2007:4066.
 78. Kato M, Katsumoto T, Ohno K, Kato S, Herz F, Takeshita K. Expression of glial fibrillary acidic protein (GFAP) by cultured angiofibroma stroma cells from patients with tuberous sclerosis. *Neuropathol Appl Neurobiol* 1992;18:559–565.
 79. Li S, Takeuchi F, Wang JA, et al. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. *J Exp Med* 2005;202:617–624.
 80. Toyoshima M, Ohno K, Katsumoto T, Maki H, Takeshita K. Cellular senescence of angiofibroma stroma cells from patients with tuberous sclerosis. *Brain Dev* 1999;21:184–191.
 81. Rosner M, Freilinger A, Hengstschrager M. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. *Mutat Res* 2006;613:10–16.
 82. Gan B, Sahin E, Jiang S, et al. mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. *Proc Natl Acad Sci USA* 2008;105:19384–19389.
 83. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. *Cancer Cell* 2003;4:147–158.
 84. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. *Cancer Res* 2003;63:5173–5177.
 85. Govindarajan B, Brat DJ, Csete M, et al. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. *J Biol Chem* 2005;280:5870–5874.
 86. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. *J Clin Invest* 1999;104:687–695.
 87. Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. *Hum Mol Genet* 2002;11:525–534.
 88. Kobayashi M, Irino T, Sweldens W. Multiscale computing. *Proc Natl Acad Sci USA* 2001;98:12344–12345.
 89. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomas, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. *Cancer Res* 1999;59:1206–1211.
 90. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. *J Clin Invest* 2003;112:1223–1233.
 91. Pollizzi K, Malinowska-Kolodziej I, Doughty C, et al. A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles. *Hum Mol Genet* 2009;18:2378–2387.
 92. Onda H, Crino PB, Zhang H, et al. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells,

- and show activation of an mTOR pathway. *Mol Cell Neurosci* 2002;21:561–574.
93. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *J Cell Biol* 2004;166:213–223.
 94. Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. *J Clin Invest* 2007;117:730–738.
 95. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. *Mol Cell Biol* 2008;28:4104–4115.
 96. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. *Proc Natl Acad Sci USA* 1994;91:11413–11416.
 97. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. *Nat Genet* 1995;9:70–74.
 98. Walker C, Goldsworthy TL, Wolf DC, Everitt J. Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. *Science* 1992;255:1693–1695.
 99. Hino O, Klein-Szanto AJ, Freed JJ, et al. Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. *Proc Natl Acad Sci USA* 1993;90:327–331.
 100. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker CL. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. *Am J Pathol* 1995;146:1556–1567.
 101. Binhazim AA, Coghlan LG, Walker C. Spontaneous hemangiosarcoma in the tail of a Long-Evans rat carrying the Eker mutation. *Lab Anim Sci* 1994;44:191–194.
 102. Yeung RS, Xiao GH, Everitt JI, Jin F, Walker CL. Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. *Mol Carcinog* 1995;14:28–36.
 103. Wenzel HJ, Patel LS, Robbins CA, Emmi A, Yeung RS, Schwartzkroin PA. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis. *Acta Neuropathol* 2004;108:97–108.
 104. Kubo Y, Mitani H, Hino O. Allelic loss at the predisposing gene locus in spontaneous and chemically induced renal cell carcinomas in the Eker rat. *Cancer Res* 1994;54:2633–2635.
 105. Kleymenova E, Ibraghimov-Beskrovnya O, Kugoh H, et al. Tuberin-dependent membrane localization of polycystin-1. A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. *Mol Cell* 2001;7:823–832.
 106. Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. *Proc Natl Acad Sci USA* 1998;95:15653–15658.
 107. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. *Am J Pathol* 1995;146:1568–1579.
 108. Crabtree JS, Jelinsky SA, Harris HA, et al. Comparison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway. *Cancer Res* 2009;69:6171–6178.
 109. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth *in vitro* and *in vivo*. *Endocrinology* 1995;136:4996–5003.
 110. Hodges LC, Houston KD, Hunter DS, et al. Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells. *Mol Cell Endocrinol* 2002;196:11–20.
 111. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. *Oncogene* 2002;21:8470–8476.
 112. Lee L, Sudentas P, Donohue B, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. *Genes Chromosomes Cancer* 2004.

Address correspondence to:

Thomas N. Darling, M.D., Ph.D.

Department of Dermatology

Uniformed Services University of Health Sciences

4301 Jones Bridge Road

Bethesda, MD 20814

E-mail: tdarling@usuhs.mil